Jefferies analyst Roger Song downgraded CureVac (CVAC) to Hold from Buy with a price target of $5, down from $7, after the company agreed to be acquired by BioNTech (BNTX). Under the terms of the agreement, each CureVac share will be exchanged for $5.46 in BioNTech shares, resulting in an implied aggregate equity value for CureVac of $1.25B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- BioNTech to Acquire CureVac in Strategic mRNA Expansion
- CureVac downgraded to Market Perform from Outperform at Citizens JMP
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
- M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal